Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2021

View Archived Issues

Study unveils a mechanistic link between LRRK2, AP2 and endocytosis in the pathogenesis of PD

Inhibition of PIP4K can be used to control regulatory T-cell activity

Novel oxidative-phosphorylation inhibitors with promising antitumor activity in vivo

Discovery of CPL-302415 as promising preclinical candidate for SLE

Loss of fbn2b tied to cardiovascular manifestations overlapping with Marfan syndrome

Eternity Bioscience patents new ADAMTS inhibitors

Fileclo Sp zoo discloses new compounds for cancer

Arbutus Biopharma identifies PD-L1 antagonists

Japanese researchers synthesize new PROTACs for cancer

Rockefeller University presents new LATS1 inhibitors

Biallelic THUMPD1 variants linked to syndromic intellectual developmental disorder

Merck & Co. structure-based design efforts lead to new nucleoside PRMT5 inhibitors

ErSO induces regression of human breast tumors in vivo

Researchers identify genetic associations with behaviors related to self-regulation and addiction

Jacobio invests in Hebecell to advance iPSC-NK cell therapy

AcureX awarded funding to support development of drug candidates for Parkinson's disease

Mindset Pharma reports preclinical data on next-generation novel 5-MeO-DMT psychedelic analogues

COL13A1 and KCNMA1 are downregulated in patients with Pompe disease

Janssen optimizes new series of PDE2A inhibitors

SPOP gene behind prostate cancer risk

All is loss for P53 mutations, study argues

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...